Ocera Therapeutics, Inc.
DelistedCIK 1274644fmd_05DG06PX36YCDZ9XKZBGMQ7JNQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2017, 31 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 9 | 10 | 0 | 0 | 0 | 0 | 1 |
| Research and development | 7 | 10 | 25 | 2 | 4 | 15 | 16 | 16 |
| Total operating expenses | 11 | 14 | 31 | 3 | 15 | 25 | 26 | 26 |
| Operating income | (10) | (5) | (21) | (19) | – | – | – | – |
| Interest expense | 2 | 1 | 2 | 2 | – | – | – | – |
| Other non-operating income (expense) | 0 | (0) | 0 | (0) | (0) | 0 | (0) | (1) |
| Income before taxes | – | (7) | (22) | (23) | (15) | (25) | – | – |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (4) | (15) | (25) | (27) | (27) |
| Net income | (11) | (7) | (22) | (4) | (18) | (23) | (27) | (27) |